News stories about AngioDynamics (NASDAQ:ANGO) have trended somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AngioDynamics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 46.5514141945141 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several equities analysts have recently weighed in on ANGO shares. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Monday, August 14th. BidaskClub upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. KeyCorp restated a “hold” rating on shares of AngioDynamics in a research note on Friday, August 25th. Finally, Canaccord Genuity restated a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a research note on Sunday, October 8th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. AngioDynamics presently has an average rating of “Hold” and an average price target of $18.60.
AngioDynamics (ANGO) traded up $0.18 during mid-day trading on Tuesday, hitting $17.21. The company had a trading volume of 241,600 shares, compared to its average volume of 234,013. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.48. The firm has a market cap of $625.27, a price-to-earnings ratio of 24.68, a PEG ratio of 1.75 and a beta of 1.04. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04). AngioDynamics had a return on equity of 4.83% and a net margin of 1.64%. The business had revenue of $85.40 million for the quarter, compared to analyst estimates of $86.12 million. During the same period in the previous year, the firm posted $0.17 earnings per share. The firm’s revenue was down 3.1% compared to the same quarter last year. research analysts predict that AngioDynamics will post 0.65 EPS for the current fiscal year.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.